LAGUNA HILLS, Calif., March 22, 2022 /PRNewswire/– Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that it has closed a $20 million funding round led by Evidity Health Capital and joined by existing and new investors. Alejandro Sanchez, Managing Director of Evidity Health Capital, will be joining PreludeDx’s Board of Directors. Proceeds from this round will be used to advance the commercial market expansion of DCISionRT® and the continued development of the company’s precision radiogenomics platform for early-stage breast cancer and other cancers. READ MORE
—